The Gradual Release of Alendronate for the Treatment of Critical Bone Defects in Osteoporotic and Control Rats
International Journal of Nanomedicine · 2023-02 · Volume 18 · 541-560
DOI: 10.2147/ijn.s386784 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Nanomedicine, 2023-02. Verfasst von Věra Hedvičáková und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Tissue Engineering, Institute of Experimental Medicine, the Czech Academy of Sciences, Prague, Czech Republic. Hauptthemen laut MEDLINE: Alendronate, Bone Density Conservation Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Purpose
Osteoporosis is a severe health problem with social and economic impacts on society. The standard treatment consists of the systemic administration of drugs such as bisphosphonates, with alendronate (ALN) being one of the most common. Nevertheless, complications of systemic administration occur with this drug. Therefore, it is necessary to develop new strategies, such as local administration.
Methods
In this study, emulsion/dispersion scaffolds based on W/O emulsion of PCL and PF68 with ALN, containing hydroxyapatite (HA) nanoparticles as the dispersion phase were prepared using electrospinning. Scaffolds with different release kinetics were tested in vitro on the co-cultures of osteoblasts and osteoclast-like cells, isolated from adult osteoporotic and control rats. Cell viability, proliferation, ALP, TRAP and CA II activity were examined. A scaffold with a gradual release of ALN was tested in vivo in the bone defects of osteoporotic and control rats.
Results
The release kinetics were dependent on the scaffold composition and the used system of the poloxamers. The ALN was released from the scaffolds for more than 22 days. The behavior of cells cultured in vitro on scaffolds with different release kinetics was comparable. The difference was evident between cell co-cultures isolated from osteoporotic and control animals. The PCL/HA scaffold show slow degradation in vivo and residual scaffold limited new bone formation inside the defects. Nevertheless, the released ALN supported bone formation in the areas surrounding the residual scaffold. Interestingly, a positive effect of systemic administration of ALN was not proved.
Conclusion
The prepared scaffolds enabled tunable control release of ALN. The effect of ALN was proved in vitro and in in vivo study supported peri-implant bone formation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Tissue Engineering, Institute of Experimental Medicine, the Czech Academy of Sciences, Prague, Czech Republic.
- Department of Chemistry, Faculty of Science, Humanities and Education, Technical University of Liberec, Liberec, Czech Republic.
- BIOFABICS Lda, Porto, Portugal.
- Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
- Department of Pathological Physiology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
- Institute of Histology and Embryology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
ORCID-Profile: Věra Hedvičáková, Maria Hovořáková, Klára Steklíková, Jitka Luňáčková, Eva Šebová, Miroslava Rysová
Zitieren
APA
Hedvičáková, V., Žižková, R., Buzgo, M., Vištejnová, L., Klein, P., Hovořáková, M., Bartoš, M., Steklíková, K., Luňáčková, J., Šebová, E., Paurová, I., Rysová, M., Filová, E., & Rampichová, M. (2023). The Gradual Release of Alendronate for the Treatment of Critical Bone Defects in Osteoporotic and Control Rats. International Journal of Nanomedicine, Volume 18, 541-560. https://doi.org/10.2147/ijn.s386784
Vancouver
Hedvičáková V, Žižková R, Buzgo M, Vištejnová L, Klein P, Hovořáková M, et al. The Gradual Release of Alendronate for the Treatment of Critical Bone Defects in Osteoporotic and Control Rats. International Journal of Nanomedicine. 2023;Volume 18:541-560. doi:10.2147/ijn.s386784
BibTeX
@article{Hedvikov2023,
author = {Hedvičáková, Věra and Žižková, Radmila and Buzgo, Matěj and Vištejnová, Lucie and Klein, Pavel and Hovořáková, Maria and Bartoš, Martin and Steklíková, Klára and Luňáčková, Jitka and Šebová, Eva and Paurová, Iveta and Rysová, Miroslava and Filová, Eva and Rampichová, Michala},
title = {The Gradual Release of Alendronate for the Treatment of Critical Bone Defects in Osteoporotic and Control Rats},
journal = {International Journal of Nanomedicine},
year = {2023},
volume = {Volume 18},
pages = {541--560},
doi = {10.2147/ijn.s386784}
}
EUVIMED